OBJECTIVE: To assess the effect of a probiotic strain Bacillus clausii UBBC-07 on gut microbiota and cytokines in IBD patients. METHOD: Patients were randomly allocated to either placebo or probiotic Bacillus clausii UBBC-07 for four weeks along with the standard medical treatment (SMT). Enrolled patients were evaluated before and after intervention for presence of the given probiotic, change in gut microbiota, change in serum cytokines, serotonin and dopamine, symptoms of disease, physical, behavioral and psychological parameters. RESULTS: Probiotic strain Bacillus clausii UBBC-07 showed good survival in IBD patients in the treatment group (p < 0.01) without any reported adverse event. Metagenomic analysis showed that the given probiotic strain was able to modulate the gut microbiota in treated group. Phylum Firmicutes was increased and phylum Bacteroidetes was decreased in the probiotic treated group. A significant increase was observed in the abundance of anaerobic bacterial genera Lactobacillus, Bifidobacterium and Faecalibacterium in the probiotic treated group (p < 0.01) as compared to placebo group. Significant increase was observed in IL-10 (p < 0.05) and variable decrease in the secretion of IL-1β, TNF- α, IL-6, IL -17 and IL -23 in probiotic treated group. In the treatment group a significant decrease in the symptoms of IBD and improvement in the psychological parameter to various degrees was noted. CONCLUSION: These results indicated that probiotic strain B clausii UBBC-07 affected the gut microbiota and cytokine secretion and shown efficacy in IBD patients.
Curated date: 2023/03/11
Revision editor(s): Brian
- Location of subjects
- Host species Species from which microbiome was sampled (if applicable)
- Homo sapiens
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- response to placebo , gestational serum measurement , gut microbiome measurement , response to serotonin , dopamine response to placebo,gestational serum measurement,gut microbiome measurement,response to serotonin,2-(3,4-Dihydroxyphenyl)ethylamine,2-(3,4-dihydroxyphenyl)ethylamine,3,4-Dihydroxyphenethylamine,3-Hydroxytyramine,4-(2-Aminoethyl)-1,2-benzenediol,4-(2-aminoethyl)-1,2-benzenediol,4-(2-Aminoethyl)benzene-1,2-diol,4-(2-aminoethyl)benzene-1,2-diol,4-(2-aminoethyl)catechol,4-(2-aminoethyl)pyrocatechol,C8H11NO2,Deoxyepinephrine,dopamina,Dopamine,dopamine,dopaminum,Hydroxytyramin
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- healthy conrols
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- response to placebo
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients were randomly allocated to either placebo or probiotic Bacillus clausii UBBC-07 for four weeks along with the standard medical treatment (SMT).
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 4 weeks
- Sequencing type
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Mass spectrometry
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Pielou Quantifies how equal the community is numerically
- Shannon Estimator of species richness and species evenness: more weight on species richness
- Chao1 Abundance-based estimator of species richness
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- Richness Number of species